Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 411

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 411
---
 share(€) | Number ofoptions | Weighted averageexercise priceper share(€) |
| From€60.00to€70.00per share        |          168,784 |                                 3.34 |                                      65.84 |          168,784 |                                      65.84 |
| From€70.00to€80.00per share        |          349,400 |                                 3.17 |                                      76.39 |          349,400 |                                      76.39 |
| From€80.00to€90.00per share        |          416,260 |                                 1.64 |                                      89.13 |          416,260 |                                      89.13 |
| Total                              |          934,444 |                                      |                                            |          934,444 |                                            |

| F-56 | SANOFIFORM 20-F2024 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

D.15.9. Number of shares used to compute diluted earnings per share

Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and

restricted shares.

| (million)                                                           |    2024 |    2023 |    2022 |
| Average number of shares outstanding                                | 1,251.4 | 1,251.7 | 1,251.9 |
| Adjustment for stock options with dilutive effect                   |     0.1 |     0.2 |     0.3 |
| Adjustment for restricted shares                                    |     4.6 |     4.5 |     4.7 |
| Average number of shares used to compute diluted earnings per share | 1,256.1 | 1,256.4 | 1,256.9 |

In 2024 , 2023 and 2022 , all stock options were taken into account in computing diluted earnings per share because they all had a

dilutive effect. D.16. N on-controlling interests Non-controlling interests did not represent a material component of Sanofi’s consolidated financial statements in the years ended December 31, 2024 , 2023 and 2022 . D.17. Debt, cash and cash equivalents and lease liabilities

D.17.1. Debt, cash and cash equivalents

Changes in Sanofi's financial position during the period were as follows:

| (€